We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of Prevnar 13 on Ear Infections in Children

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01272999
First Posted: January 10, 2011
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Pfizer
December 8, 2010
January 10, 2011
October 12, 2017
December 2010
December 2013   (Final data collection date for primary outcome measure)
  • S pneumoniae serotype for each isolate assayed [ Time Frame: Annual (12 months from study start) ]
  • S pneumoniae serotype for each isolate assayed [ Time Frame: Annual (24 months from study start) ]
  • S pneumoniae serotype for each isolate assayed [ Time Frame: Annual (36 months from study start) ]
  • The primary endpoint is the S pneumoniae serotype for each isolate assayed [ Time Frame: Annual (12 months from study start) ]
  • The primary endpoint is the S pneumoniae serotype for each isolate assayed [ Time Frame: Annual (24 months from study start) ]
  • The primary endpoint is the S pneumoniae serotype for each isolate assayed [ Time Frame: Annual (36 months from study start) ]
Complete list of historical versions of study NCT01272999 on ClinicalTrials.gov Archive Site
  • The antimicrobial susceptibility patterns for each isolate [ Time Frame: Study Completion (36 months from study start) ]
  • The primary clinical diagnosis of each child from whom S pneumoniae is isolated [ Time Frame: Study Completion (36 months from study start) ]
Same as current
Not Provided
Not Provided
 
Impact of Prevnar 13 on Ear Infections in Children
Postmarketing Observational Study Of The Impact Of Prevnar 13 (Pneumococcal 13 Valent Conjugate Vaccine) On Otitis Media In Children
Prevnar (7 valent pneumococcal conjugate vaccine [7vPnC]) has been shown to be effective against ear infections in children. Prevnar 13 is a new vaccine that is similar to Prevnar. It is expected that the effectiveness of Prevnar 13 against ear infections in children will be similar to that observed following Prevnar. Pfizer has committed to conduct a postmarketing study of the impact of Prevnar 13 in reducing ear infections among children.
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   None Retained
Description:
Microbiology samples (middle ear fluid) taken by treating physicians in standard course of care for ear infections.
Non-Probability Sample
Children aged 6 weeks to 18 years
  • Acute Otitis Media
  • Mastoiditis
Not Provided
1
Otitis media cases
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
391
December 2013
December 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Case eligibility should be based on microbiologic data and should be reviewed and documented by an appropriately qualified member of the investigator's study team before cases are included in the study database.
  • S pneumoniae identified from middle ear fluid or mastoiditis sample.
  • Specimen obtained from children aged up to 18 years.

Exclusion Criteria:

  • As this is an observational, laboratory based database study, there are no exclusion criteria
Sexes Eligible for Study: All
6 Weeks to 18 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01272999
6096A1-4024
B1851040
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
September 2014